Spinocerebellar Ataxia Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DM2226 | Last Updated On: Nov 01 2022 | Available Formats

> Global Spinocerebellar Ataxia Market Expected to reach a high CAGR by 2029: DataM Intelligence

Global Spinocerebellar Ataxia Market is segmented By Test(Treatment, Diagnostic Test, End-User), By Diagnostic Test (Hospitals, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2029


Market Overview

The "Global Spinocerebellar Ataxia Market" is expected to grow at a high CAGR during the forecasting period (2022-2029).

Spinocerebellar Ataxia Market Scope




Market CAGR


Segments Covered

By Test,By Diagnostic Test and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Get A Free Sample Click Here

Spinocerebellar Ataxia is a genetic disorder that is progressive, degenerative, and often fatal. The clinical marker of all SCAs is a progressive loss of balance and coordination accompanied by slurred speech. Individuals with an SCA's mobility and communicative skills are restricted, which strongly impairs quality of life, and many SCAs lead to premature death.

Spinocerebellar ataxia type 1 (SCA1) is a subtype of type I autosomal dominant cerebellar ataxia (ADCA type I; see this term) characterized by dysarthria, writing difficulties, limb ataxia, and commonly nystagmus and saccadic abnormalities.

Spinocerebellar ataxia type 3, also called the Machado-Joseph disease (MJD), is an inherited form of ataxia characterized by progressive clumsiness in the arms and legs. MJD is usually classified into three types, including Type I, Type II, and Type III. Type I usually starts at the age of 10-30 years with faster progression and more dystonia and rigidity than ataxia. Type II is the most common type of MJD.

Market Dynamics

The global spinocerebellar ataxia diagnosis and treatment market can be segmented based on:

  • Treatment
  • Diagnostic Test
  • End-user

In terms of treatment, the global spinocerebellar ataxia diagnosis and treatment market can be bifurcated into:

  • Adaptive devices
  • Therapies
  • Physical Therapy
  • Occupational Therapy
  • Speech Therapy

Physical therapy can help individuals suffering from spinocerebellar ataxia in improving coordination and enhanced mobility. Occupational therapy can help individuals suffering from spinocerebellar ataxia in conducting daily tasks such as feeding themselves. Speech therapy for people suffering from spinocerebellar ataxia helps in improving speech and aids in swallowing.

Based on the diagnostic test, the global spinocerebellar ataxia diagnosis and treatment market can be divided into:

  • Imaging Tests
  • Magnetic Resonance Imaging (MRI),
  • Computed Tomography (CT) Scan
  • X-ray
  • Positron Emission Tomography (PET) scan
  • Lumbar Puncture Tests
  • Genetic Tests

In terms of end-user, the global spinocerebellar ataxia diagnosis and treatment market can be segmented into:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Market Segmentation

Spinocerebellar Ataxia starts between about 20 and 50 years and has an intermediate progression rate.  Type III starts at the age of 40-70 years and progresses relatively slowly. Consequently, the condition's rising incidences are further likely to boost the drug development for spinocerebellar ataxia in the next few years.

It has been observed that spinocerebellar ataxia (SCA) is a hereditary disease caused due to mutations in the ATXN1 gene. Mutation in the ATXN1 gene can lead to degenerative changes in the cerebellum and spinal cord. A person affected by the disease usually inherits the altered gene from an affected parent. The gene is passed from one generation to the next. According to the NIH, one to two per 100,000 people worldwide are affected by spinocerebellar ataxia.

Geographical Analysis

North America holds the dominant market share for Spinocerebellar Ataxia (SCA) in 2019 and is expected to maintain the growth over the forecast period, increasing the prevalence of Spinocerebellar Ataxia. 

Spinocerebellar Ataxia in the report solely focuses on the market revenue generated by the pharmacological treatment (including off-label symptomatic therapies, such as Neuroprotective agents, Nicotine Receptor Agonists, Serotonergic Therapy, and GABAergic Therapy) used for SCA management in the diagnosed cases. Upcoming therapies like Troriluzole (BHV-4157; Biohaven Pharmaceuticals) and KPS-0373 (Rovatirelin; Kissei Pharmaceuticals)

Competitive Landscape

Some of the major manufacturers in Bioblast Pharma, Shionogi, WAVE Life Sciences, Biohaven Pharmaceuticals, Cadent Therapeutics, Ionis Pharmaceuticals, Spark Therapeutics and Lacerta Therapeutics.

The key players are adopting various growth strategies such as new product launches, mergers & acquisitions, partnerships, and collaborations contributing to the growth of the Spinocerebellar Ataxia market globally.

SCAR16 is a monogenetic disorder - a condition resulting from modifications in a single gene known as STUB1. This gene produces the protein CHIP and is found in nearly all cells of the body. CHIP is a multi-functional enzyme, monitors and regulating the quality of proteins important for human health, particularly in age-related diseases. It was unclear if changes in the different activities of CHIP contribute to the clinical spectrum of SCAR16 and what activities may be potential therapeutic targets.

Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, affects about one in 20,000 people. There's no disease-modifying therapy available, and patients slowly progress to an early death. A single gene mutation causes this neurodegenerative disease, making it an ideal target for a group of University of Michigan researchers.

Why Purchase the Report?

  • Visualize the composition of the Spinocerebellar Ataxia (SCA) market segmentation Treatment Type and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in Spinocerebellar Ataxia (SCA) market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of Spinocerebellar Ataxia (SCA) market points - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The Global Spinocerebellar Ataxia (SCA) Market report would provide access to an approx. 47 market data table, 39 figures and 286 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Frequently Asked Questions

What is the Projected CAGR value of the Spinocerebellar Ataxia Market?

Spinocerebellar Ataxia Market is expected to grow at a CAGR of high during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Spinocerebellar Ataxia Market during 2022-2029.

Which is the fastest growing region in the Spinocerebellar Ataxia Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period.

Trending Topics

Diagnostic Imaging Market

Diagnostic Electrophysiology Catheters Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!